Formulation development of chitosan coated intra nasal ropinirole nanoemulsion for better management option of Parkinson: An In vitro ex vivo evaluation

Current Nanoscience

Volumn 8, Issue 3, 2012, Pages 348-360

  Mustafa, Gulam ^a   Baboota, Sanjula ^a   Ahuja, Alka ^a,b   Ali, Javed ^a  

^a HAMDARD UNIVERSITY   (India)

^b OMAN MEDICAL COLLEGE   (Oman)

Author keywords

Intratracheal intubation model; Nanoemulsion; Phase diagram; Ropinirole; Thermodynamic stability; Transmission electron microscopy

Indexed keywords

HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY; PHASE DIAGRAMS; SURFACE ACTIVE AGENTS; THERMODYNAMIC STABILITY; TRANSMISSION ELECTRON MICROSCOPY;

BLOOD-BRAIN BARRIER; FORMULATION DEVELOPMENT; INTRATRACHEAL INTUBATION MODELS; NANOEMULSION; PARKINSON'S DISEASE; ROPINIROLE; TERNARY PHASE DIAGRAMS; THERMODYNAMICALLY STABLE;

DRUG PRODUCTS;

CHITOSAN; COSURFACTANT; DIETHYLENE GLYCOL MONOETHYL ETHER; OIL; POLYSORBATE 80; ROPINIROLE; WATER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG COATING; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; EX VIVO STUDY; IN VITRO STUDY; NANOEMULSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; VISCOSITY;

RATTUS;

EID: 84861683682     PISSN: 15734137     EISSN: 18756786     Source Type: Journal    
DOI: 10.2174/157341312800620331     Document Type: Article

References (50)

1. Obeso, J. A.; Rodrigquez-Oroz, M. C.; Rodriguez, M.; Lanciego, J. L.; Artieda, J.; Gonzolo, N.; Olnow, C. W. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci., 2000, 23, 8-19.
2. Fearnley, J. M.; Lees, A. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain, 1991, 114, 2283-2301.
3. Jenner, P.; Olanow, C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology, 1996, 47(6), 161-170.
4. Bandmann, O.; Marsden, D.C.; Wood, N.W. Genetic aspects of Parkinson's disease. Mov. Disord., 1998, 13, 203-211.
5. Ziv, I.; Melamed, E.; Nardi, N. Role of apoptosis in the pathogenesis of Parkinson's disease: a novel therapeutic opportunity. Mov. Disord., 1998, 13, 865-870.
6. Calne, D. B.; Langston, J. W. Aetiology of Parkinson's disease. Lancet., 1983, 2, 1457-1459.
7. Bergman, H.; Deuschl, G. Pathophysiology of Parkinson's disease: From clinical neurology to basic neuroscience and back. Mov. Disord., 2002, 17, 28-40.
8. Graff, C.L.; Pollack, G. M. Nasal drug administration: potential for targeted central nervous system delivery. J. Pharm. Sci., 2005, 94, 1187-1195.
9. Kemper, E. M.; van Zandbergen, A. E.; Cleypool, C.; Mos, H. A.; Boogerd, W.; Beijnen, J. H.; van Tellingen, O. Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin. Cancer Res., 2003, 9, 2849-2855.
10. Kumar, M.; Misra, A.; Babbar, A.K.; Mishra, A.K.; Mishra, P.; Pathak, K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int. J. Pharm., 2008, 358, 285-291.
11. Soni, V.; Chaurasia, M. K.; Gupta, Y.; Jain, A.; Kohli; D. V.; Jain; S.K.; Novel approaches for drug delivery to the brain. Ind. J. Pharm. Sci., 2004, 66, 711-720.
12. Jain, A.; Jain, S. K. Drug Targeting to the Brain-A Review. Curr. Nanosci., 2011, 7(1), 21-36.
13. Shinde, R. L.; Jindal, A. B.; Devarajan, P.V. Microemulsions and Nanoemulsions for Targeted Drug Delivery to the Brain. Curr. Nanosci., 2011, 7(1), 119-133.
14. Malhotra, M.; Prakash, S. Targeted Drug Delivery Across Blood-Brain-Barrier Using Cell Penetrating Peptides Tagged Nanoparticles. Curr. Nanosci., 2011, 7(1), 81-93.
15. Sakane, T.; Akizuki, M.; Yoshida, M.; Yamashita, S.; Nadai, T.; Hashida, M.; Sezaki, H. Transport of cephalexin to the cerebrospi nal fluid directly from the nasal cavity. J. Pharm. Pharmacol., 1991, 43, 449-451.
16. Illum, L. Nasal drug deliveryαpossibilities, problems and solutions. J. Control. Release, 2003, 87, 187-198.
17. Hussain, A.; Kimura, R.; Huang, C.H.; Mustafa, R. Nasal absorption of ergotamine tartrate in rats. Int. J. Pharm., 1984, I, 289-293.
18. Henriksson, J.; Tallkvist, J.; Tjalve, H. Uptake of nickel into the brain via olfactory neurons in rats. Toxicol. Lett., 1997, 91, 153-162.
19. Chow, H.S.; Chen, Z.; Matsuura, G.T. Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J. Pharm. Sci., 1999, 88, 754-758.
20. Hussain, A. A. Intranasal drug delivery. Adv. Drug Deliv. Rev., 1998, 29, 39-49.
21. Soane, R. J.; Carney, A. S.; Jones, N. S.; Perkins, A. C.; Frier, M.; Davis, S. S.; Illum, L. The effect of the nasal cycle on mucociliary clearance. Otolaryngological Research Society, London, 1998.
22. Hussain, A.; Kimura, R.; Haung, C. H. Nasal absorption of testosterone in rats. J. Pharm. Sci., 1984a; 73 (9), 1300-1301.
23. Azeem, A.; Rizwan, M.; Ahmad, F. J.; Iqbal, Z.; Khar, R. K.; Aqil, M.; Talegaonkar, S. Nanoemulsion Components Screening and Selection: a Technical Note. AAPS Pharm. Sci. Tech., 2009, 10, 1093-1103.
24. Talegaonkar, S.; Mustafa, G.; Akhter, S.; Iqbal, Z. I. Design and Development of Oral Oil-in-Water Nanoemulsion Formulation Bearing Atorvastatin: In vitro Assessment. J. Disp. Sci. Tech., 2009, 30, 1-12.
25. Shakeel, F.; Baboota, S.; Ahuja, A.; Ali, J.; Shafiq, S. Celecoxib nanoemulsion: skin permeation mechanism and bioavailability assessment. J. Drug Target., 2008, 16(10), 733-740.
26. Shafiq, S.; Faiyaz, S.; Sushma, T.; Farhan, J. A.; Khar, R. K.; Mushir, A. Design and development of ramipril nanoemulsion formulation: in vitro and in vivo assessment. J. Biomed. Nanotech., 2007, 3, 28-44.
27. Mustafa, G.; Khan, Z. I.; Bansal, T.; Talegaonkar, S. Preparation and Characterization of Oil in Water Nano-Reservoir Systems for Improved Oral Delivery of Atorvastatin. Curr. Nanosci., 2009, 5, 428-440.
28. Dhabi, M. R.; Milan, D. L.; Navin, R. S. Preparation and In vivo Evaluation of Self-Nanoemulsifying Drug Delivery System (SNEDDS) Containing Ezetimibe. Curr. Nanosci., 2011, 7 (4), 616-627.
29. Sambhaji, P.; Shelke, V.; Mahadik, K.; Kadam, S. Effect of Organogel Components on In vitro Nasal Delivery of Propranolol Hydrochloride. AAPS Pharm. Sci. Tech., 2004, 5 (4), 63.
30. Wadell, C.; Erik-Bjork, E.; Camber, O. Permeability of porcine nasal mucosa correlated with human nasal absorption. Eur. J. Pharm. Sci., 2003, 18, 47-53.
31. Figueiras, A.; Hombach, J.; Veiga, F.; Bernkop-Schnurch, A. In vitro evaluation of natural and methylated cyclodextrins as buccal permeation enhancing system for omeprazole delivery. Eur. J. Pharm. Biopharm., 2009, 71(2), 339-345.
32. Biruss, B.; Valenta, C. Comparative characterization of the physicochemical behavior and skin permeation of extruded DPPC liposomes modified by selected additives. J. Pharm. Sci., 2007, 96 (8), 2171-2176.
33. Hussain, A.; Hirai, S.; Bawarshi, R. Nasal absorption of propranolol from different dosage forms by rats and dogs. J. Pharm. Sci., 1980, 69, 1411-1413.
34. Kenneth, S. E.; Kristina, M. S.; Campanale, C. L. G. Nasal drug delivery system of a quaternary ammonium compound: clofilium tosylate. J. Pharm. Sci., 1984, 73 (9), 1251-1254.
35. Chien, Y. W. Transnasal systemic medication, Elsevier; Amsterdam/Oxford/New York/Tokyo/1985.
36. Jain, S.; Mittal, A.; Jain, A. K.; Mahajan, R. R.; Singh, D. Cyclosporin A Loaded PLGA Nanoparticle: Preparation, Optimization, In Vitro Characterization and Stability Studies. Curr. Nanosci., 2010, 6 (4), 422-431.
37. Constantinides, P. P. Lipid Microemulsions for Improving Drug Dissolution and Oral Absorption: Physical and Biopharmaceutical Aspects. Pharm. Res., 1995, 12, 1561-1572.
38. Xi, J.; Chang, Q.; Chan, C.K.; Meng, Z.Y.; Wang, G.N.; Sun, J.B.; Wang, Y.T.; Tong, H.H.Y.; Zheng, Y. Formulation development and bioavailability evaluation of a self-nanoemulsified drug delivery system of oleanolic acid. AAPS Pharm. Sci. Technol., 2009, 10, 172-182.
39. Wen, A. D.; Jia, Y. Y.; Luo, X. X.; Bi, L. L.; Chen, X. Y.; Zhong, D. F. The effect of Madopar on the pharmacokinetics of ropinirole in healthy Chinese volunteers. J. Pharm. Biomed. Anal., 2007, 43(2), 774-778.
40. Eccleston, G. M. Microemulsions, in Swarbrick, S.; Boylan, J.C. Encyclopedia of Pharmaceutical Technology. 1st ed., Marcel Dekker, INC, New York, NY, 1992, pp. 375-421.
41. Rang, M. J.; Miller, C. A. Spontaneous emulsification of oils containing hydrocarbon, non-ionic surfactant, and oleyl alcohol. J. Coll. Interface Sci., 1999, 209, 179-192.
42. Gao, Z.G.; Choi, H.G.; Shin, H.J.; Park, K.M.; Lim, S.J.; Kim, C.K. Physicochemical characterization and evaluation of amicroemulsion system for oral delievery of cyclosporin A. Int. J. Pharm., 1998, 161, 75-86.
43. Craig, D. Q. M.; Barker, S. A.; Banning, D.; Booth, S. W. An investigation into the mechanism of self-emulsification using particle size analysis and low frequency dielectric spectroscopy. Int. J. Pharm., 1995, 114, 103-110.
44. Feng, S.; Huang, G. Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J. Control. Release, 2001, 71, 53-69.
45. Lin, H.; Gebhardt, M.; Bian, S,; Kwon, K. A.; Shim, C. K.; Chung, S. J.; Kim, D. D. Enhancing effect of surfactants on fexofenadine. HCl transport across the human nasal epithelial cell monolayer. Int. J. Pharm., 2007, 330 (1-2), 23-31.
46. Hussain, A.; Kimura, R.; Huang, C. H.; Kashihara, T, Nasal absorption of naloxone and buprenorphine in rats. Int. J. Pharm., 1984b, 21(2), 233-237.
47. Morimoto, K.; Morisaka, K.; Kamada, A. Enhancement of nasal absorption of insulin and calcitonin using polyacrylic acid gel. J. Pharm. Pharmacol., 1985, 37(2), 134-136.
48. Visor, G. C.; Schuessler, B.; Thompson, J.; Ling, T. Nasal Absorption of the Calcium Antagonist Nicardipine in Rats and Rhesus Monkeys. Drug Dev. Ind. Pharm., 1987, 13 (8), 1329-1243.
49. Olivier, V.; Meisen, I.; Meckelein, B.; Hirst, T. R.; Peter-Katalinic, J.; Schmidt, M. A.; Frey, A. Influence of targeting ligand flexibility on receptor binding of particulate drug delivery systems. Bioconjug. Chem., 2003, 14 (6), 1203-1218.
50. Chen, X. Q.; Fawcett, J. R.; Rahman, Y. E.; Ala, T. A.; Frey II, W. H. Delivery of Nerve Growth Factor to the Brain via the Olfactory Pathway. J. Alzheimers Dis., 1998, 1(1), 35-44.